Sign In
Last checked at 
30 Jun 2025 12:22
For immediate release
EMV Capital plc
("EMVC" or the "Company")
Result of Annual General Meeting
EMV Capital Plc (AIM: EMVC), the deep tech and life sciences VC investment group, announces that all resolutions set out in the 2025 Notice of Annual General Meeting sent to shareholders were duly passed at the Company's Annual General Meeting held earlier today.
Result of Annual General Meeting
Resolutions 1 to 9 were passed as Ordinary Resolutions and Resolution 10 was passed as a Special Resolution. The proxy voting results are as follows:
Resolution | For | % | Against | % | Vote Total | Vote Total as % of Issued Share Capital | Withheld* |
1. To receive and adopt the Company's Annual Report and Accounts for the period ended 31 December 2024
| 8,703,874 | 100.0% | 1,617 | 0.0% | 8,705,491 | 31.4% | 266 |
2. To receive and approve the Directors' Remuneration Report
| 8,585,144 | 98.8% | 106,993 | 1.2% | 8,692,137 | 31.3% | 13,620 |
3. To reappoint BDO LLP as the auditors for the forthcoming year
| 8,696,626 | 99.9% | 8,865 | 0.1% | 8,705,491 | 31.4% | 266 |
4. To authorise the Audit Committee in determining the Auditors' remuneration
| 8,694,933 | 100.0% | 2,558 | 0.0% | 8,697,491 | 31.3% | 8,266 |
5. To confirm the reappointment of Dr Charles Spicer as a director
| 8,689,567 | 99.9% | 6,617 | 0.1% | 8,696,184 | 31.3% | 9,573 |
6. To confirm the reappointment of Dr Ilian Iliev as a director
| 8,689,567 | 99.9% | 6,617 | 0.1% | 8,696,184 | 31.3% | 9,573 |
7. To confirm the reappointment of Edward Hooper as a director
| 8,689,567 | 99.9% | 6,617 | 0.1% | 8,696,184 | 31.3% | 9,573 |
8. To confirm the reappointment of Dr Jonathan Robinson as a director
| 8,689,567 | 99.9% | 6,617 | 0.1% | 8,696,184 | 31.3% | 9,573 |
9. To authorise the Directors to allot relevant securities pursuant to section 551 of the Companies Act 2006
| 8,178,221 | 95.2% | 414,852 | 4.8% | 8,593,073 | 30.9% | 112,684 |
10. To disapply pre-emption rights on the allotment of securities or sale of treasury shares in connection with a pre-emptive offer or on allotment of up to 5,553,460 shares
| 8,233,170 | 94.7% | 456,228 | 5.3% | 8,689,398 | 31.3% | 16,359 |
* A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.
For more information, please contact:
| |
EMV Capital plc | via Rosewood |
Ilian Iliev, CEO |
|
|
|
Panmure Liberum Limited (NOMAD and Broker) | +44 (0)20 7886 2500 |
Emma Earl / Will Goode / Freddy Crossley / Mark Rogers (Corporate Finance) |
|
Rupert Dearden (Corporate Broking) |
|
|
|
Rosewood (Financial PR) | +44 (0)20 7653 8702 |
John West / Llewellyn Angus / Lily Pearce | |
About EMV Capital plc (EMVC)
EMV Capital plc, is a deep tech and life sciences venture capital investment group with an international portfolio of high-growth companies.
With a strategic focus on generating superior returns for investors from the fast-growing sectors and technologies that will define our future; EMV Capital invests in, manages and strengthens early-stage IP-rich companies.
EMV Capital holds both direct equity stakes and carried interest in its portfolio companies, creating an evergreen structure that supports extensive growth and value creation. EMV Capital's investment thesis is realised through these capital sources:
· capital-efficient investments through Group balance sheet;
· fund management of the Evergreen EIS and Martlet Capital Funds;
· syndicated investments leveraging its network of third-party investors.
EMV Capital's approach is characterised by its proactive management style, aiming to advance portfolio companies to critical value inflection points by actively engaging with them. Companies are supported through Board representation and the use of its Value Creation Services practice.
Headquartered in London, with a Cambridge presence and strong international links, EMV Capital is quoted on the AIM market of the London Stock Exchange.
www.emvcapital.com
Follow the stocks
